|
|
|
|
|
|
THE FINANCIER |
Research doctors from the Fred Hutchinson Cancer Research Center started at least 10 major
companies, many with help from The Hutch and New York financiers David and Isaac Blech. |
Company |
Stock |
Value |
52-week high |
Founded |
Blech $ connection |
Hutch $ connection |
Genetic Systems |
GSC |
$294 million(a) |
1980 |
yes |
Licenses, royalties |
Immunex |
IMNX |
$13.2 billion |
$44.9 billion |
1981 |
|
Experiments |
NeoRX |
NERX |
$147 million |
$1.8 billion |
1984 |
yes |
Clinical trials |
Targeted Genetics |
TGEN |
$174 million |
$1.0 billion |
1989 |
|
Licensing, contracts |
ICOS |
ICOS |
$2.3 billion |
$3.1 billion |
1989 |
yes |
|
CellPro |
CPRO |
$284 million(b) |
1989 |
|
Stock, licenses, royalties |
Cell Therapeutics |
CTIC |
$485 million |
$2.2 billion |
1991 |
yes |
Stock, licenses, royalties |
PathoGenesis (Chiron) |
CHIR |
$700 million(c) |
1992 |
yes |
|
Corixa |
CRXA |
$512 million |
$2.4 billion |
1994 |
|
|
Rosetta Inpharmatics |
RSTA |
$278 million |
$1.2 billion |
1996 |
|
Stock, licenses, royalties |
a) Sale price to Bristol-Myers in 1986. Bristol-Myers resold the company in 1991 for $20 million.
(b) 1997 value. Went bankrupt in 1998, after losing patent-infringement lawsuit.
(c) Sale price to Chiron in August 2000. Chiron has market cap of $8.3 billion. |
Sources: Seattle Times research, SEC reports, Nasdaq closing values 3/13/01. The Hutchinson Center will not reveal stock holdings
or license and royalty deals, so this chart is incomplete. |
|
|
|